CN Patent

CN114786679A — 具有维奈托克和tim-3抑制剂的组合疗法

Assigned to Novartis AG · Expires 2022-07-22 · 4y expired

What this patent protects

本发明公开了包含TIM‑3抑制剂的组合疗法。所述组合可用于治疗包括血液癌的癌病症和障碍。

USPTO Abstract

本发明公开了包含TIM‑3抑制剂的组合疗法。所述组合可用于治疗包括血液癌的癌病症和障碍。

Drugs covered by this patent

Patent Metadata

Patent number
CN114786679A
Jurisdiction
CN
Classification
—
Expires
2022-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.